Search / Trial NCT06224790

Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy

Launched by SIDRAH LODHI · Jan 16, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Type 2 Diabetes Mellitus Diabetic Nephropathy Perfenidone

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Diabetic Nephropathy Stage 3 (eGFR 30-59 mL/min/1.73m2) Type 2 Diabetes HbA1c \<7.5% Patient taking ACEi/ARB for at least 3 months BP \<140/90
  • Exclusion Criteria:
  • * History of photosensitivity rash History of decompensated liver or cardiac disease History of urinary tract infection Pregnancy or lactation History of nephrotoxic drugs or hakeem medication Polycystic kidney disease History of autoimmune disease History of hypersensitivity to study drugs

About Sidrah Lodhi

Sidrah Lodhi is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative clinical studies. With a focus on ethical practices and regulatory compliance, Sidrah Lodhi collaborates with leading research institutions and healthcare professionals to design and implement trials that explore new therapies and treatment modalities. Their comprehensive approach emphasizes patient safety, robust data collection, and transparent reporting, ensuring that each trial contributes valuable insights to the medical community and enhances the overall understanding of disease management and intervention strategies.

Locations

Lahore, Punjab, Pakistan

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0